Children's Mercy to Treat 5X More Kids With Gene Therapies

Children's Mercy in Kansas City just announced a major expansion that could bring one-time cures to five times more children with rare diseases and aggressive cancers.

The hospital is partnering with Basepath Health to scale up its cell and gene therapy program, treatments that target the root cause of disease rather than just managing symptoms. For many kids, that means a single treatment could halt or even reverse conditions that once required a lifetime of care.

These therapies work by modifying a patient's own cells or delivering working genes to replace faulty ones. Children's Mercy currently offers several FDA-approved treatments for conditions like sickle cell disease, certain cancers, and neuromuscular disorders.

The problem is access. Only a limited number of hospitals can provide these highly specialized treatments, and families often face long waits or must travel far from home. The therapies require complex coordination across months of care, from patient identification through long-term monitoring.

That's where the partnership comes in. Basepath Health will provide AI-powered tools to streamline scheduling, navigation, and tracking, freeing up doctors and nurses to focus on patient care. The goal is to reduce wait times and administrative burden while maintaining the highest clinical standards.

Dr. Shabnam Arsiwala, who directs Children's Mercy's Sickle Cell Disease Program, sees the expansion as a turning point. "We're treating the root cause, not just the symptoms," she said. "We're focused on helping more families access these therapies while surrounding every patient with comprehensive, family-centered support."

Children's Mercy began offering cell and gene therapy over a decade ago and has steadily grown its program. In the past year alone, the hospital delivered these personalized treatments to dozens of patients. With the expansion, they aim to treat hundreds more over the next four years.

The Ripple Effect

This expansion extends beyond Kansas City. As one of the Midwest's leading pediatric centers, Children's Mercy serves families across multiple states who would otherwise need to travel to major coastal hospitals for these treatments.

By building capacity in the heartland, the partnership creates a model other regional hospitals might follow. That could mean thousands more children nationwide gaining access to therapies that were once out of reach.

The timing matters too. More cell and gene therapies are in the pipeline, with new treatments expected to gain FDA approval in coming years. Building the infrastructure now prepares Children's Mercy to offer new cures as soon as they become available.

For families who once measured hope in symptom-free days, the prospect of a single curative treatment changes everything.